We collected four external independent immune therapy cohorts (anti-PD-1/PD-L1/CTLA-4) and a clinical cohort of advanced HNSCC patients receiving immune therapy to evaluate the performance of DRGs in predicting immune therapy response. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.